Page 112 - Haematologica Vol. 109 - July 2024

ARTICLE - MUD versus haplo PT-CY stem cell transplantation in children with AML A. Ruggeri et al. Table 2. Patients and transplant characteristics in the matched pair cohort.
Variables Modalities
MUD N=253 Haplo PT-CY N=95 N (%) N (%)
Age in years at HCT Median (IQR) 11.2 (4.9-14.6) 10 (3-15.4)
0-7 87 (34.4)
Age in years at HCT 7-12 51 (20.2)
12-18 115 (45.5)
31 (32.6)
24 (25.3)
40 (42.1)
Disease status at HCT
CR1 178 (70.4) 69 (72.6)
CR2 75 (29.6) 26 (27.4)
No 26 (16)
Molecular remission Yes 136 (84)
Missing 91
7 (12.5)
49 (87.5)
39
Year of HCT Median (IQR) 2017 (2014-2019) 2018 (2017-2020)
Parent
Relation to donor Sibling
Missing
- 69 (83.1)
- 14 (16.9)
- 12
Median (IQR)
Donor age in years Range
Missing
27 (23.2-34.2)
18.4-57.4
48
35.7 (29.5-42.89
4.4-54.3
13
Source of cells
BM 163 (64.4) 62 (65.3)
PB 90 (35.6) 33 (34.7)
Patient sex
Female 123 (48.6) 44 (46.3)
Male 130 (51.4) 51 (53.7)
Female donor to male recipient
No 217 (85.8) 68 (71.6)
Yes 36 (14.2) 27 (28.4)
Lansky or KPS
<90 62 (24.5) 15 (15.8)
≥90 191 (75.5) 80 (84.2)
CMV IgG match donor-recipient
Neg to Neg
Neg to Pos
Pos to Neg
Pos to Pos
50 (19.8)
64 (25.3)
35 (13.8)
104 (41.1)
7 (7.4)
7 (7.4)
10 (10.5)
71 (74.7)
Cytogenetic risk
Good
Intermediate
Poor
Missing
30 (13.7)
123 (56.2)
66 (30.1)
34
15 (20.3)
36 (48.6)
23 (31.1)
21
CSA+MTX based
CSA based
GVHD prophylaxis CSA+MMF based
CSA+MMF+MTX based
Other
169 (66.8)
46 (18.2)
11 (4.3)
3 (1.2)
24 (9.5)
1 (1.1)
5 (5.3)
49 (51.6)
3 (3.2)
37 (38.9)
BuCyMel based
BuCy based
Conditionning regimen BuFlu based Treo based
Other combinations
89 (35.2)
71 (28.1)
36 (14.2)
51 (20.2)
6 (2.4)
1 (1.1)
10 (10.5)
63 (66.3)
18 (18.9)
3 (3.2)
MUD: matched unrelated donors; haplo: haploidentical; PT-CY: post-transplant cyclophosphamide, HCT: hematopoietic stem cell transplan- tation; IQR: interquartile range; CR: complete remission; BM: bone marrow; PB: peripheral blood; KPS: Karnofsky Performance status, CMV: cytomegalovirus; CSA: cyclosporin; MTX: methotrexate, MMF: mycophenolate mofetile; Bu: busulfan; Flu: fludarabine; Cy: cyclophosphamide; Mel: melphalan; Treo: treosulfan; Pos: positive; Neg: negative.
Haematologica | 109 July 2024
2126